Published a new study on Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy

10/02/2023 Publications Published a new study on Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy KINETO Lab took a part in development of Bombesin-Based Peptide–Drug Conjugates, acting as drug delivery systems to safely reach the tumour environment. Two of bioconjugates revealed remarkable anti-proliferative activity, an efficient uptake by all three tested human breast and prostate cancer cell lines, high stability in plasma and a prompt release of the drug-containing metabolite by lysosomal enzymes. Moreover, they revealed a safe profile and a consistent reduction of the tumour volume in vivo. The publication can be accessed under the following link. PreviousNext

Published a new study on Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo

07/11/2022 Publications Published a new study on Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo By applying the computational methods in order to search for dual-inhibitors that could prevent the production of hazardous Aβ42 peptides and avoid their aggregation, it was developed molecules which inhibit AChE and BACE-1 enzymes, while the most potent molecule shows a reduction in brain tissue of soluble Aβ42 in mice. The publication can be accessed under the following link. PreviousNext

Announced publication in Vaccines (Basel) on A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine

07/09/2022 Publications Announced publication in Vaccines (Basel) on A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine We are pleased to announce that our newest paper in the journal Vaccines (Basel) is now published online. This study provides proof-of-concept for the efficacy of the ‘Win the Skin Immune System Trick’ (WISIT) vaccine technology platform, which induces potent immune responses and therapeutic efficacy in mice, and support further preclinical and clinical development of this vaccine candidate. The publication can be accessed under the following link. PreviousNext